—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Moderna Inc (MRNA) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for MRNA, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 2.10 to TLT · on the worst bond days it held up better than the market

How it trades on rate days

How MRNA has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 2.10 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Moderna Inc moved 2.10% on average · correlation 0.25 · higher than 99% of US names
  • Beta, last 3 months 3.31 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.07% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +6.98% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · United States · 8 names with week and year-to-date

Peer group

Biotechnology · United States

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against MRNA on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Moderna Inc

MRNA in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Moderna develops messenger RNA medicines, a technology that instructs cells to make a protein rather than delivering the protein itself. Its portfolio spans respiratory vaccines for COVID, RSV and influenza, vaccines against latent viruses and other pathogens, and early oncology and rare-disease programmes. It works with partners including Merck, Vertex and government health agencies, and has a collaboration with OpenAI. The company is based in Cambridge, Massachusetts.
Where it sits in the stack
Moderna carries no seat in Rubin, our AI build-out index, or in Halo, so it sits outside the stack this diary tracks; its peer group in our universe is Biotechnology, United States.
Who it is priced against
Closelooknet groups it with US biotechnology names — Sarepta, Exelixis, Incyte, Biomarin, Jazz Pharmaceuticals and others — ranked on trend state rather than a score, since the cohort has none; the market also compares it with BioNTech as the other mRNA-platform vaccine maker.
Why Closelooknet tracks it
Moderna is an S&P 500 constituent but carries no Closelooknet score, so the diary reads it through trend state — its distance from the 50- and 200-day averages — rather than any module reading.
What the diary watches
Whether new vaccine approvals or the oncology and rare-disease pipeline start to show up in the trend readings the diary already tracks for this name.

Moderna Inc (MRNA) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-20. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 14 analyst actions on the wire · latest: initiation by Deutsche Bank, 2026-08-28

The Street on this name

Analyst actions and the latest print for MRNA from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Initiation Deutsche Bank — at Hold Initiated to Hold from Hold 2026-08-28
  • Initiation William Blair — at Outperform Initiated to Outperform from Outperform 2026-08-28
  • Initiation UBS — at Neutral Initiated to Neutral from Neutral 2026-08-25

14 actions on the analyst wire since 2026-08-13: 4 upgrades, 2 downgrades, 5 initiations, 3 target changes. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Moderna Inc (MRNA)?

Moderna Inc trades as MRNA on the US exchange (United States) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is MRNA in a Closelooknet index?

Not currently — Moderna Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does MRNA trade against its moving averages?

Uptrend stack intact: Trades +80.6% vs the 50-day and +209.5% vs the 200-day average, 1.9% below the 52-week high and +792.6% off the 52-week low. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Moderna Inc trade when bond yields rise?

Over the past year Moderna Inc had a beta of 2.10 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 99% of US names. On the 10 sessions in which long bonds fell most it moved −0.07% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Moderna Inc do?

Moderna develops messenger RNA medicines, a technology that instructs cells to make a protein rather than delivering the protein itself. Its portfolio spans respiratory vaccines for COVID, RSV and influenza, vaccines against latent viruses and other pathogens, and early oncology and rare-disease programmes. It works with partners including Merck, Vertex and government health agencies, and has a collaboration with OpenAI. Closelooknet groups it with US biotechnology names — Sarepta, Exelixis, Incyte, Biomarin, Jazz Pharmaceuticals and others — ranked on trend state rather than a score, since the cohort has none; the market also compares it with BioNTech as the other mRNA-platform vaccine maker.

Where does Moderna Inc sit in the AI build-out?

Moderna carries no seat in Rubin, our AI build-out index, or in Halo, so it sits outside the stack this diary tracks; its peer group in our universe is Biotechnology, United States. Moderna is an S&P 500 constituent but carries no Closelooknet score, so the diary reads it through trend state — its distance from the 50- and 200-day averages — rather than any module reading.

What has Wall Street done on Moderna Inc recently?

The most recent analyst action on Moderna Inc on the Closelooknet wire is a initiation by Deutsche Bank on 2026-08-28 (at Hold). 14 actions on the analyst wire since 2026-08-13: 4 upgrades, 2 downgrades, 5 initiations, 3 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for MRNA, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.